RT Journal Article
SR Electronic
T1 Adjuvant Chemotherapy for Endometrial Cancer: Unproven
JF International Journal of Gynecologic Cancer
JO Int J Gynecol Cancer
FD BMJ Publishing Group Ltd
SP 1105-1108
OP 1105-1108
DO 10.1111/IGC.0b013e3181f35473
VO 20
IS 7
A1 Carien L. Creutzberg
YR 2010
UL http://ijgc.bmj.com/content/20/7/1105-1108.abstract
AB High-risk endometrial cancer (EC), only 15% of all EC, mainly affects elderly women, often with significant comorbid diseases. Because patients with high-risk EC are at increased risk of distant metastases and EC death, the use of adjuvant chemotherapy has been investigated in several trials. Trials comparing radiotherapy and chemotherapy have not shown survival difference. A first trial comparing combinations of chemotherapy and radiotherapy with radiotherapy alone suggested progression-free survival benefit. Toxicity and quality of life data are lacking. The role of adjuvant chemotherapy for endometrial carcinoma remains unproven. High-risk EC remains the challenge for further research.